A trial shows that esketamine/dexmedetomidine reduces inflammation and cognitive issues in surgery patients, suggesting a new approach.
Esketamine/dexmedetomidine-based OFA markedly attenuates peri-operative IL-6 and NSE surges and is associated with a lower incidence of early POCD after TLH. These mechanistic findings warrant confirmation in a definitive randomized trial.
No takes yet. Share an insight, caveat, or question.
LI et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: